State creates new oversight offices for drugs and health‑resource planning; HPC and CHIA seek staff and funding to implement mandates

David Seltz, executive director of the Health Policy Commission (HPC), and Lauren Peters, executive director of the Center for Health Information and Analysis (CHIA), told the Joint Committee on Ways and Means that the legislature’s recent healthcare legislation significantly expands both agencies’ missions and will require modest additional resources to implement.

New responsibilities at a glance - Pharmaceutical analysis and transparency: Seltz said the law creates an Office of Pharmaceutical Policy and Analysis (OPA) within HPC to examine the full drug supply chain — manufacturers, PBMs, wholesalers and pharmacies — with fresh data and policy analysis. The office will advise state purchasers (MassHealth, Group Insurance Commission) and policymakers and aims to produce objective, system‑wide facts about pricing and flows.

- Health resource planning: The legislation creates an Office of Health Resource Planning to develop state‑level planning for where services and facilities are needed, and to conduct rapid assessments tied to facility closures. Seltz said the office will help the state be proactive about closures and capacity gaps and co‑chair new task forces on maternal and primary care access.

- Expanded market oversight and private equity transparency: Both Seltz and Peters said the new market‑oversight requirements direct CHIA to collect expanded financial information from private‑equity investors, real‑estate entities and other stakeholders affiliated with providers to give a more complete financial picture of hospitals, nursing facilities and other providers.

Why the changes matter Seltz framed the reforms as a continuation of the 2012 cost‑containment framework (the state’s health care cost‑growth benchmark) and said the two 2025 bills represent the biggest expansions since 2012. He described pharmaceutical spending and primary care decline as major drivers of cost and health inequities and said stronger, independent data and analytic capacity will empower policy action.

Budget and implementation - HPC requested modest funding to staff the new OPA and the Office of Health Resource Planning; Seltz said expanded assessments will ultimately help cover costs of the new functions because the agencies are funded by healthcare assessments rather than the general fund. - CHIA requested increases to implement its new data‑collection duties (PBM reporting, expanded financials for private‑equity affiliates) and to finish a new sector workforce survey and improved dashboards for hospitals and nursing facilities. Lauren Peters said CHIA’s FY26 request reflects new legislative requirements enacted after House 1 and that the agency is prepared to implement the new reporting mandates.

Legislator questions and topics Committee members asked about prescription drug cost trends, including rapid growth in GLP‑1 weight‑loss medications and the distribution of benefits across payers (wrong‑pocket problems). Seltz said the HPC will study utilization, pricing and long‑term fiscal implications and that international price differences change the calculus of cost‑benefit for novel drug classes. Representative Russell Holmes and others asked whether HPC would have the data and authority to scrutinize PBMs and 340B arrangements; Seltz and Peters said the new law expands CHIA and HPC reporting and oversight tools to get that information and to support evidence‑based policy.

What comes next Seltz said the law takes effect imminently and HPC will stand up offices and staffing to begin analysis and rapid assessments; CHIA said it will begin collecting the newly required data streams and preparing dashboards and workforce survey results for early FY26 reporting.